GynOnc Paper Review: PRIMA скачать в хорошем качестве

GynOnc Paper Review: PRIMA

PRIMA Gonzalez-Martin et al., (2019): https://www.nejm.org/doi/full/10.1056... PRIMA (PRIMAry debulking surgery versus neoadjuvant chemotherapy in ovarian carcinoma) is a clinical trial in gynecologic oncology that is investigating the optimal treatment approach for women with advanced ovarian cancer. One aspect of the trial is evaluating the use of the PARP inhibitor niraparib in addition to standard chemotherapy and surgery. PARP inhibitors are a type of targeted therapy that work by blocking an enzyme called poly(ADP-ribose) polymerase (PARP), which is involved in repairing damaged DNA. By inhibiting PARP, cancer cells are prevented from repairing their DNA, which can lead to cell death. Niraparib is a PARP inhibitor that has been shown to improve progression-free survival (PFS) in women with recurrent ovarian cancer. In the PRIMA trial, women with advanced ovarian cancer are being randomized to receive either primary debulking surgery (PDS) followed by chemotherapy and placebo or PDS followed by chemotherapy and niraparib. The aim of this part of the trial is to determine if adding niraparib to standard treatment improves PFS and other outcomes for women with advanced ovarian cancer. The results of this aspect of the PRIMA trial could have important implications for the use of PARP inhibitors in the first-line treatment of ovarian cancer. If the addition of niraparib is found to improve outcomes, it could become a standard treatment option for women with advanced ovarian cancer. However, it is important to note that the trial is ongoing, and more data will be needed before any conclusions can be drawn.